Autolus Therapeutics to participate in Investor Conferences through January

LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.

• 11 January 2021 – The company will present at the H.C. Wainwright BioConnect 2021 Conference which will be available on demand as of 6:00 am ET, 11 am GMT on Monday, January 11, 2021. The webcast will be available on the investor relations section of the Company’s website at Autolus.
  
  
• 13 January 2021 – The company will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 9:10 am ET, 2.10 pm GMT. The Company will host virtual one-on-one meetings at the J.P. Morgan event and a live audio webcast will be available on the investor relations section of the Company’s website at Autolus.
  

Archived replays will be available for a period of 30 days after the conferences.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
[phone] 
[e-mail]

Julia Wilson
[phone]
[e-mail]

Susan A. Noonan
S.A. Noonan Communications
[phone]
[e-mail]